Matching Items (2)
Filtering by

Clear all filters

137656-Thumbnail Image.png

Investigate and characterize the means to reduce the toxicity of genetically engineered cancer therapeutic recombinant attenuated Salmonella

Description
Cancer is one of the leading causes of death in the world and represents a tremendous burden on patients, families and societies. S. Typhimurium strains are specifically attracted to compounds produced by cancer cells and could overcome the traditional therapeutic barrier. However, a major problem with using live attenuated Salmonella…

Cancer is one of the leading causes of death in the world and represents a tremendous burden on patients, families and societies. S. Typhimurium strains are specifically attracted to compounds produced by cancer cells and could overcome the traditional therapeutic barrier. However, a major problem with using live attenuated Salmonella as anti-cancer agents is their toxicity at the dose required for therapeutic efficacy, but reducing the dose results in diminished efficacy. In this project, we explored novel means to reduce the toxicity of the recombinant attenuated Salmonella by genetically engineering those virulence factors to facilitate maximal colonization of tumor tissues and reduced fitness in normal tissues. We have constructed two sets of Salmonella strains. In the first set, each targeted gene was knocked out by deletion of the gene. In the second set, the predicted promoter region of each gene was replaced with a rhamnose-regulated promoter, which will cease the synthesis of these genes in vivo, a rhamnose-free environment.
ContributorsBenson, Lee Samuel (Author) / Kong, Wei (Thesis director) / Martin, Thomas (Committee member) / Lake, Douglas (Committee member) / Barrett, The Honors College (Contributor) / Department of Psychology (Contributor) / Center for Infectious Diseases and Vaccinology (Contributor) / School of Life Sciences (Contributor)
Created2013-05

Arntzen, Charles

Description

Charlie Arntzen joined ASU in August 2000 as the Florence Ely Nelson Presidential Endowed Chair and retired in 2016 from the School of Life Sciences and Biodesign Institute. Charlie was the founding Director of the Biodesign Institute.
Important ASU stories include:
1) the creation of the Biodesign Institute,
2) the design and operation…

Charlie Arntzen joined ASU in August 2000 as the Florence Ely Nelson Presidential Endowed Chair and retired in 2016 from the School of Life Sciences and Biodesign Institute. Charlie was the founding Director of the Biodesign Institute.
Important ASU stories include:
1) the creation of the Biodesign Institute,
2) the design and operation of the Biodesign labs,
3) the development of ZMapp to fight Ebola,
4) The New American University - a discussion of the importance of collaboration, and
5) several comments about Presidents Coor and Crow and Provost Glick
ContributorsChurch, Kathy (Interviewer) / Arizona State University Retirees Association (Producer)
Created2019-05-08